A Randomized, Double-blind, Multicenter, Placebo-controlled Trial (PRESS-PD)
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and widely used neuromodulation technology. Small sample studies have shown that rTMS treatment can significantly improve the symptoms of Parkinson's disease(PD) and delay the progression of the disease. In order to further explore the effectiveness of rTMS in the treatment of PD and lay the foundation for its clinical promotion, our research team plans to conduct a randomized double-blind controlled study of rTMS in the treatment of PD in multiple centers across the country.
• Age ≥ 40 years old;
• Meet the diagnostic criteria for idiopathic Parkinson's disease (MDS Diagnostic Criteria for Parkinson's Disease (2015 Edition))\[1\];
• Have no history of drug adjustment within 4 weeks before treatment and the entire study period;
• The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4;
• MMSE ≥22，able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy.